Deutsche Bank
TRAX icon

Deutsche Bank’s First Tracks Biotherapeutics TRAX Stock Holding History

Deutsche Bank’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.65M Buy
159,375
+97,258
+157% +$3.8M ﹤0.01% 1185
2026
Q2 		$1.25M Buy
+62,117
New +$1.16M ﹤0.01% 2212

Other funds holding TRAX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Deutsche Bank's TRAX Position: Q3 2026 in Review

Deutsche Bank increased its First Tracks Biotherapeutics (TRAX) stake by 157% in Q3 2026, buying an estimated $3.8M and bringing the position to 159,375 shares worth $5.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1185.

Deutsche Bank first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 118 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

  • Deutsche Bank held 159,375 shares of First Tracks Biotherapeutics worth $5.65M as of Q3 2026.
  • Deutsche Bank bought 97,258 First Tracks Biotherapeutics shares in Q3 2026, an estimated $3.8M.
  • First Tracks Biotherapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #1185 holding.
  • Deutsche Bank first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • 118 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.